Skip to main content
Signal8
Launch Terminal

DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

NASDAQ:DMACHealthcare
-2.84%$9.25
AH$9.25+0.00%vs close
Mkt Cap$498.81M
Float24.33M
O/S53.93M
Vol
$ Vol
RVOL
Inst Own23.1%
SI21.6%
Earnings
Dilution
DiaMedica Therapeutics Inc. logoNASDAQ:DMAC$9.25-2.84%
Upcoming Catalysts
Phase Distribution
7 lead-sponsored trials·1 active·5 completed
Phase 12
Phase 1/21
Phase 22
Phase 2/31
Not applicable1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2/3
    Recruiting

    Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

    Recombinant human tissue kallikrein

    Acute Stroke, Ischemic Stroke +1

    Enrollment
    728
    Start
    Nov 2021
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT05065216
  • Phase 2
    Completed

    Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

    Recombinant human tissue kallikrein

    Acute Ischemic Stroke

    Enrollment
    92
    Start
    Jan 2018
    Primary Completion
    Jan 2020
    Completion
    Jan 2020
    NCT03290560
  • Phase 2
    Completed

    Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

    DM199

    Kidney Diseases

    Enrollment
    79
    Start
    Dec 2019
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT04123613
  • Phase 1/2
    Completed

    A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients

    DM199, Placebo

    Diabetes Type 2

    Enrollment
    98
    Start
    Apr 2013
    Primary Completion
    Sep 2014
    Completion
    Nov 2014
    NCT01845064
  • Phase 1
    Completed

    An Open Label, Phase 1b, Ascending Dose Study of DM199

    Recombinant human tissue kallikrein

    Stroke

    Enrollment
    36
    Start
    Sep 2016
    Primary Completion
    Mar 2017
    Completion
    Mar 2017
    NCT02868996
  • Phase 1
    Completed

    Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

    DM199

    Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate) +2

    Enrollment
    33
    Start
    Feb 2019
    Primary Completion
    Jul 2019
    Completion
    Jul 2019
    NCT03795389
  • Not applicable
    Withdrawn

    DM199 for Pregnancy Complications

    DM199

    Pre-Eclampsia

    Enrollment
    0
    Start
    May 2025est.
    Primary Completion
    May 2025est.
    Completion
    May 2025est.
    NCT06875141
Search ClinicalTrials.gov for “DiaMedica Therapeutics”